Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Has Consensus Target Price of $13.86

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received an average rating of “Hold” from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $13.86.

Several equities analysts have recently commented on the company. Needham & Company LLC lowered their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Zacks Research downgraded Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Wall Street Zen raised Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd.

Institutional Trading of Bicycle Therapeutics

Several hedge funds have recently bought and sold shares of BCYC. Renaissance Technologies LLC grew its position in shares of Bicycle Therapeutics by 72.8% during the first quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock valued at $4,544,000 after purchasing an additional 412,700 shares in the last quarter. Rangeley Capital LLC raised its holdings in shares of Bicycle Therapeutics by 76.0% during the 1st quarter. Rangeley Capital LLC now owns 232,260 shares of the company’s stock worth $1,078,000 after acquiring an additional 100,260 shares in the last quarter. Marquette Asset Management LLC purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $309,000. ADAR1 Capital Management LLC bought a new position in shares of Bicycle Therapeutics during the 1st quarter valued at approximately $331,000. Finally, Principal Financial Group Inc. boosted its position in shares of Bicycle Therapeutics by 2.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company’s stock valued at $5,450,000 after acquiring an additional 26,353 shares during the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

BCYC opened at $3.65 on Thursday. Bicycle Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $9.08. The firm’s fifty day moving average is $3.86 and its 200 day moving average is $4.64. The stock has a market cap of $255.46 million, a price-to-earnings ratio of -1.34 and a beta of 1.68.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The firm had revenue of $0.63 million during the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. On average, equities research analysts predict that Bicycle Therapeutics will post -2.26 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.